CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of “Hold” from Brokerages


Shares of CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) have been given an average rating of “Moderate Buy” by the twenty analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $98.22.

CRSP has been the topic of a number of recent research reports. EF Hutton Acquisition Co. I assumed coverage on shares of CRISPR Therapeutics in a research note on Thursday, January 5th. They set a “buy” rating and a $75.00 price target on the stock. Citigroup cut their price target on CRISPR Therapeutics from $83.00 to $63.00 and set a “neutral” rating for the company in a report on Wednesday, November 23rd. SVB Leerink boosted their price objective on CRISPR Therapeutics from $75.00 to $76.00 and gave the company an “outperform” rating in a research note on Monday, November 7th. Credit Suisse Group decreased their price target on CRISPR Therapeutics from $90.00 to $78.00 in a research report on Wednesday, November 2nd. Finally, JMP Securities cut their price objective on shares of CRISPR Therapeutics from $100.00 to $70.00 and set a “market outperform” rating for the company in a research report on Thursday, January 19th.

Insider Activity

In related news, CEO Samarth Kulkarni sold 25,000 shares of CRISPR Therapeutics stock in a transaction on Wednesday, December 28th. The shares were sold at an average price of $40.93, for a total value of $1,023,250.00. Following the transaction, the chief executive officer now owns 369,111 shares in the company, valued at approximately $15,107,713.23. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its stake in shares of CRISPR Therapeutics by 8.2% during the second quarter. Steward Partners Investment Advisory LLC now owns 1,944 shares of the company’s stock valued at $118,000 after acquiring an additional 148 shares during the last quarter. HC Advisors LLC raised its position in CRISPR Therapeutics by 2.1% during the 2nd quarter. HC Advisors LLC now owns 7,432 shares of the company’s stock valued at $452,000 after purchasing an additional 154 shares during the last quarter. Bouvel Investment Partners LLC lifted its holdings in CRISPR Therapeutics by 1.0% in the 3rd quarter. Bouvel Investment Partners LLC now owns 18,726 shares of the company’s stock worth $1,224,000 after buying an additional 190 shares during the period. Cetera Investment Advisers increased its stake in shares of CRISPR Therapeutics by 3.0% during the second quarter. Cetera Investment Advisers now owns 8,064 shares of the company’s stock valued at $490,000 after buying an additional 237 shares during the period. Finally, E Fund Management Co. Ltd. raised its holdings in shares of CRISPR Therapeutics by 3.6% during the third quarter. E Fund Management Co. Ltd. now owns 7,113 shares of the company’s stock valued at $465,000 after acquiring an additional 245 shares in the last quarter. 71.51% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $52.78 on Friday. CRISPR Therapeutics has a 1 year low of $38.94 and a 1 year high of $86.95. The stock’s fifty day moving average price is $48.90 and its two-hundred day moving average price is $60.27. The firm has a market cap of $4.13 billion, a PE ratio of -6.00 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last announced its quarterly earnings data on Tuesday, November 1st. The company reported ($2.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.30) by $0.06. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $3.53 million. CRISPR Therapeutics had a negative return on equity of 31.34% and a negative net margin of 4,831.79%. Sell-side analysts anticipate that CRISPR Therapeutics will post -9.25 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Further Reading

Analyst Recommendations for CRISPR Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Read more here: Source link